The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
"BASECAMP is limited to identifying patients that are candidates, doing the analysis, looking for HLA loss... and then harvesting those cells via leukapheresis and storing those cells until the patient has a progression. At that time... a board of several of us will discuss if the patient is going to be a good candidate or not.”
BASECAMP-1 is identifying patients with relapsed solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH) as a future target for mesothelin (MSLN) and carcinoembryonic antigen (CEA)-targeted Tmod chimeric antigen receptor (CAR) T-cell therapies. The study was presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14, 2021, by Julian Molina, MD, PhD, professor, oncology, Mayo Clinic.
A2 Biotherapeutics also announced preclinical data on the Tmod system at SITC 2021 that demonstrated its robust protective effect on surrogate normal human cells in vitro, even in mixed-cell populations, while also yielding a robust cytotoxic effect on tumor cells in xenograft models.
GeneTherapyLive spoke with Molina to learn more about the BASECAMP-1 study and how it will inform and increase efficiency in future trials assessing Tmod technology.